Quest Diagnostics Incorporated Q2 FY26 Earnings Analysis

- Q1 2026 organic volume growth was strong at 10.8%, with total volume growth at 10.9%. - Excluding Corewell and Fresenius partnerships, organic volume growth was 3.8%. - Fresenius and Corewell collaborations contribute approximately 7% to organic volume growth. - Revenue guidance for 2026 raised to $11.78B to $11.9B, reflecting 6.8% to 7.8% growth. - Continued strong growth expected in physician, hospital, and consumer health channels. - Advanced diagnostics and consumer health segments show strong double-digit growth. - Partnerships and collaborations, including with wellness and wearable companies, expected to further accelerate growth. - Higher test per requisition driven by advanced tests and screening options supports revenue per requisition growth. - Corewell and Fresenius expected to add approximately $330-$350 million combined revenue growth in 2026. - Seasonality: Just over 49% of revenue and EPS in the first half, slightly over 50% in the second half, with continued strong organic utilization.

- Full year 2026 revenue guidance raised to $11.78 billion - $11.9 billion, a growth rate of 6.8% to 7.8%. - Reported EPS guidance updated to $9.58 - $9.78. - Adjusted EPS guidance raised to $10.63 - $10.83, reflecting strong first quarter momentum. - Operating margin expected to expand versus prior year. - Productivity gains from automation and AI to support earnings growth. - Project Nova investments expected to cause $0.25 EPS dilution for 2026, with expenses ramping more in second half. - Margin profile improvements anticipated, especially from partnerships (e.g., Fresenius) as businesses ramp. - EPS improvement expected over course of the year but early to quantify dilution or improvement specifics. - No M&A contribution included in 2026 guidance; M&A pipeline remains active but cautious. - Fuel cost inflation embedded in guidance; estimated $0.05 to $0.07 EPS impact.

- $550 million capital expenditures forecasted for 2026, consistent with 2025 levels (Page 3). - Significant portion of capital investments allocated to esoteric labs for capacity upgrades to support advanced diagnostics growth (Page 11). - Continued investments in advanced diagnostics, including brain health biomarkers (AB 42/40, ApoE, NFL, p-tau181/217), cardiometabolic testing, and oncology partnerships (Page 11). - Ongoing support for Haystack cancer detection test, including commercial ramp and reimbursement efforts (Page 11-12). - Scaling planning and design for Project Nova, a multi-year initiative to transform order-to-cash processes with first wave implementation expected in fall 2027 (Page 3, 6). - No specific M&A contribution included in 2026 guidance, but M&A funnel remains active with ongoing evaluations of health system outreach deals (Page 12).

- The transcript does not mention any current or planned fundraising through debt or equity. - 2026 guidance includes expectations for cash from operations (~$1.75 billion), capital expenditures (~$550 million), and consistent share count and interest expense compared to 2025. - There is no indication of new debt issuance or equity offerings within the provided pages. - The company states that 2026 revenue guidance does not include any contribution from prospective M&A, suggesting a cautious approach to growth but no explicit fundraising plans. - Overall, no explicit plans for new fundraising via debt or equity are disclosed in the discussed call.

The provided document does not explicitly mention details about the current or expected order book or pending orders. However, insights related to demand and growth can be inferred: - Solid first quarter results indicate strong demand for diagnostic solutions. - Organic volume growth was 10.8% in Q1 2026, showing broad-based utilization increases. - Growth driven by Corewell Health and Fresenius Medical Care collaborations contributing around 7% to volume growth. - Consumer health and wellness partnerships, including wearables and AI-driven testing, are expanding. - Increased longitudinal testing and test-per-patient trends due to AI, wearables, and consumer-initiated testing are expected. - Ongoing M&A activities with a healthy funnel of potential deals, though no contributions forecasted in 2026 guidance. - Project Nova and AI initiatives suggest future operational efficiency improvements, potentially supporting order processing. No specific figures for order backlog or pending orders are disclosed in the document.